Um consórcio internacional identificou o bavisant, um fármaco já conhecido para distúrbios do sono, como capaz de promover a remielinação e proteger neurónios em modelos de EM. Em paralelo, a Universidade de Helsínquia descobriu duas moléculas que ta...

There is a major unmet medical need for the progressive forms of MS. Therapeutics aimed at supporting myelin regeneration and neuroprotection are a potential solution. The histamine receptor H3 antago

There is a major unmet medical need for the progressive forms of MS. Therapeutics aimed at supporting myelin regeneration and neuroprotection are a potential solution. The histamine receptor H3 antago

A new computational hunt for a multiple sclerosis therapy Researchers have used in silico screening to identify a promising drug candidate, bavisant, for the treatment of multiple sclerosis. The candidate was subsequently validated in preclinical models, demonstrating its potential to modulate the disease process. This approach highlights the growing role of computational methods in accelerating the discovery of new therapeutics for complex neurological conditions.

A new computational drug candidate emerges for multiple sclerosis Researchers have used in silico screening to identify a compound called bavisant as a

Researchers found the drug bavisant helps nerve protection and myelin repair in lab and mouse studies, supporting trials to slow MS-related disability.

The histamine receptor H3 antagonist bavisant promotes neuroprotection and remyelination in cell and mouse models of multiple sclerosis.

Come ricercatori del San Raffaele hanno identificato bavisant, un farmaco che agisce su degenerazione nervosa e rimielinizzazione

The histamine receptor H3 antagonist bavisant promotes neuroprotection and remyelination in cell and mouse models of multiple sclerosis.

Une molécule dont les effets étaient, jusqu’ici, étudiés dans le cadre des troubles du sommeil et du déficit de l’attention avec ou sans hyperactivité, révèle pour la première fois son potentiel dans ...

Una breve analisi sull'evoluzione della ricerca sulla sclerosi multipla: ruolo del glucosio, inibitori della BTK, staminali, Bavisant. Senza dimenticare le persone che provano a vivere dentro un corpo che cambia.

Bavisant e trattamento della Sclerosi Multipla Cos’è il Bavisant Il Bavisant (noto anche come JNJ-31001074 o BEN-2001) è un antagonista/inverse